Oruka Therapeutics, Inc.: management transactions · United States · SEC (Form 4)

About Oruka Therapeutics, Inc.

Oruka Therapeutics, Inc. (Nasdaq: ORKA) is a United States-based clinical-stage biotechnology company listed on the NASDAQ market in the United States. The company is focused on developing novel biologic antibodies intended to raise the standard of care in chronic inflammatory skin diseases, with an initial emphasis on plaque psoriasis and a broader ambition to address adjacent dermatology and inflammatory indications. Oruka states that its corporate headquarters are in Menlo Park, California, and that it also maintains an office in Waltham, Massachusetts. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0000907654/000121390026026929/ea0273300-10k_oruka.htm?utm_source=openai)) Oruka is a young company from a corporate-history standpoint. It was incorporated in Delaware on February 6, 2024, and later changed its name from ARCA biopharma, Inc. to Oruka Therapeutics, Inc. following a merger completed in August 2024; at the same time, its Nasdaq ticker changed from ABIO to ORKA. For equity investors, this matters because Oruka remains a clinical development story rather than a commercial-stage company, with value creation tied primarily to execution in the clinic and, ultimately, in regulatory and commercial pathways. ([ir.orukatx.com](https://ir.orukatx.com/static-files/3449d816-a887-40f4-8c45-ac408cade0bb?utm_source=openai)) The pipeline is centered on two co-lead assets. ORKA-001 is a half-life-extended IL-23p19 monoclonal antibody designed for plaque psoriasis. Oruka has reported positive interim Phase 1 data and, more recently, positive Week 16 data from the ongoing EVERLAST-A Phase 2a study, showing strong efficacy and a favorable safety profile consistent with the class. The company has also indicated that the PK/PD profile continues to support the possibility of very infrequent dosing, potentially as rare as annual maintenance in psoriasis. ORKA-002 is a half-life-extended IL-17A/F monoclonal antibody, being developed for moderate-to-severe psoriasis and potentially hidradenitis suppurativa (HS). ([ir.orukatx.com](https://ir.orukatx.com/news-releases/news-release-details/oruka-therapeutics-announces-positive-week-16-data-orka-001?utm_source=openai)) From a competitive perspective, Oruka is targeting highly established biologic classes in dermatology. That means the company is not trying to invent a new disease category; rather, it is trying to win on differentiation through durability, dosing convenience, and potentially best-in-class clinical response. In psoriasis, those attributes are commercially important because chronic therapy adherence, patient convenience, and depth of skin clearance are major purchasing and prescribing criteria. Oruka does not yet generate product revenue, so the investment case remains dependent on clinical success, regulatory milestones, and, later, manufacturing and commercialization readiness. ([ir.orukatx.com](https://ir.orukatx.com/news-releases/news-release-details/oruka-therapeutics-reports-fourth-quarter-and-full-year-2025?utm_source=openai)) Recent milestones are notable. In February 2026, Oruka initiated the Phase 2 ORCA-SURGE trial for ORKA-002 in psoriasis. In April 2026, it announced positive Week 16 results for ORKA-001 from EVERLAST-A. In its March 2026 update, the company reported $479.6 million in cash, cash equivalents, and marketable securities as of December 31, 2025, which provides a substantial funding runway for a company at this stage. Overall, Oruka is a focused U.S. NASDAQ biotech with a concentrated dermatology pipeline, early but encouraging clinical data, and a long-duration balance sheet relative to its development stage. ([ir.orukatx.com](https://ir.orukatx.com/news-releases/news-release-details/oruka-therapeutics-reports-fourth-quarter-and-full-year-2025?utm_source=openai))